KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Receivables - Other (2016 - 2025)

Gsk has reported Receivables - Other over the past 10 years, most recently at $1.5 billion for Q4 2025.

  • For Q4 2025, Receivables - Other rose 38.7% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, up 38.7%, while the annual FY2025 figure was $1.5 billion, 38.7% up from the prior year.
  • Receivables - Other for Q4 2025 was $1.5 billion at Gsk, up from $1.1 billion in the prior quarter.
  • Over five years, Receivables - Other peaked at $1.7 billion in Q4 2021 and troughed at $1.1 billion in Q4 2024.
  • A 5-year average of $1.4 billion and a median of $1.4 billion in 2022 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: decreased 15.74% in 2022 and later surged 38.7% in 2025.
  • Year by year, Receivables - Other stood at $1.7 billion in 2021, then dropped by 15.74% to $1.4 billion in 2022, then fell by 9.81% to $1.3 billion in 2023, then dropped by 15.19% to $1.1 billion in 2024, then soared by 38.7% to $1.5 billion in 2025.
  • Business Quant data shows Receivables - Other for GSK at $1.5 billion in Q4 2025, $1.1 billion in Q4 2024, and $1.3 billion in Q4 2023.